

JC07 Re PCT/PTO 29 APR 2005

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

10/521922

PCT/FR03/002358 25 July 2003 26 July 2002
INTERNATIONAL APP. NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED
SPECIFIC ISOTYPE ANTIBODIES OF SECRETION-EXCRETION ANTI-ANTIGENS
OF *LEISHMANIA SP* OF PROMASTIGOTE OR AMASTIGOTE FORMS...
TITLE OF INVENTION
PAPIEROK, Gérard; VICENS, Serge; LEMESRE, Jean-Loup
APPLICANT(S)

TRANSMITTAL OF INFORMATION DISCLOSURE FORM

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450
ATTENTION: DO/US

U.S. Serial No.: 10/521922
Filed on: 20 January 2005


Sir:

Attached please find the enclosed Information Disclosure Form, PTO/SB/08A or its equivalent, as applied to the above-identified application.

APR 27 2005

Date

Respectfully submitted,



John S. Egbert
Reg. No. 30,627
Harrison & Egbert
412 Main St., 7th Floor
Houston, Texas 77002
(713)224-8080
(713)223-4873 (Fax)

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)


I hereby certify that the attached INFORMATION DISCLOSURE STATEMENT is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450



on APR 27 2005

APR 27 2005

Date



John S. Egbert

Please type a plus sign (+) inside  → 

PTO/SB/08B (10-96)
App. for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/521922
				Filing Date	20 January 2005
				First Named Inventor	PAPIEROK, Gerard et al
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	1811-61

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DEPLAZES, P. et al, "Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites." PARASITE IMMUNOLOGY (England), vol. 17, no. 9, September 1995, pp. 451-458.	
		JIMENEZ-RUIZ, A. et al, "Cloning, sequencing, and expression of the PSA genes from Leishmania infantum." EUROPEAN JOURNAL OF BIOCHEMISTRY (Germany), vol. 251, no. 1-2, 15 January 1998, pp. 389-397.	
		KEMP, M. et al, "The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognized by Th1 cells in humans with naturally acquired immunity to L. major." FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (Netherlands), vol. 20, no. 3, March 1998, pp. 209-218.	
		CIBRELUS, P. et al, "Secreted antigens of the amastigote and promastigote forms of Leishmania infantum inducing a humoral response in humans and dogs." PARASITE (France), vol. 6, no. 2, June 1999, pp. 121-129.	
		RIERA, C. et al, "Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate" VETERINARY PARASITOLOGY (Netherlands), vol. 84, no. 1-2, July 1999, pp. 33-47.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.